ellaOne Laboratoire HRA Pharma · Authorised · authorised 15 May 2009 · ATC G03AD02
Therapeutic indication (EMA)
Emergency contraception within 120 hours (five days) of unprotected sexual intercourse or contraceptive failure.
Active substance
Ulipristal
- SFDA 2
- US FDA 2
- EMA 3
- Health Canada 1
- US price lines 1
- NHS prices 1
- WHO EML 1
- Safety 1
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| Ecinq | 30 mg | Film-coated tablet · Oral use | 1 Blister | SAR 51.15 | Generic · OTC | Aspen Healthcare | Valid |
| ESMYA 5 MG TABLET | 5 mg | Tablet · Oral use | 28 Blister | SAR 432.90 | NCE · Prescription | Ferring GmbH | Withdrawn by regulatory authority · Not Marketed |
Indications — CHI Daman Drug Formulary
CONTRACEPTION
US FDA United States — FDA approvals (Drugs@FDA)
EMA European Union — centrally authorised medicines
Esmya Gedeon Richter Ltd · Withdrawn · authorised 22 Feb 2012 · ATC G03XB02
Therapeutic indication (EMA)
Ulipristal acetate is indicated for pre-operative treatment of moderate to severe symptoms of uterine fibroids in adult women of reproductive age. Ulipristal acetate is indicated for intermittent treatment of moderate to severe symptoms of uterine fibroids in adult women of reproductive age.
Ulipristal Acetate Gedeon Richter Gedeon Richter Plc. · Withdrawn · authorised 27 Aug 2018 · ATC G03XB02
Therapeutic indication (EMA)
Ulipristal acetate is indicated for one treatment course of pre-operative treatment of moderate to severe symptoms of uterine fibroids in adult women of reproductive age. Ulipristal acetate is indicated for intermittent treatment of moderate to severe symptoms of uterine fibroids in adult women of reproductive age who are not eligible for surgery.
Canada Canada — marketed products (Health Canada)
| Brand | DIN | Strength | Form · route | Company |
|---|---|---|---|---|
| ELLA | 02436329 | 30 MG | TABLET · ORAL | LABORATOIRE HRA PHARMA |
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| US NADAC | ELLA 30 MG TABLET | $37.09804 | per EA | 23 Sep 2026 |
| NHS Drug Tariff | Ulipristal 30mg tablets | £16.58 | 1 tablet | 1 Oct 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
WHO WHO Model List of Essential Medicines (2025)
- 22.1.1. Oral hormonal contraceptives · core
Contact with health services for postcoital contraception
Oral > Solid: 30 mg tablet (ulipristal acetate)
Safety signals and safety-related labeling changes
- US FDA 24 Jun 2021 ELLA — safety-related labeling change
Labeling sections changed: Warnings and Precautions; Adverse Reactions; Drug Interactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.